Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
| IMMUNIC, INC.IMUX · Entity 6306 | Director · Executive Chairman | July 16, 2025 | July 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
IMMUNIC, INC.
Report date July 16, 2025 · Filed July 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-07-16 | Direct | 315,000 |
Reported balance
After 2025-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-16 · Grant · Acquired 315,000 · Balance 315,000 F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-07-16 | Direct | 630,000 |
Reported balance
After 2025-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-16 · Grant · Acquired 630,000 · Balance 630,000 F2: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof. F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-07-16 | Direct | 630,000 |
Reported balance
After 2025-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-16 · Grant · Acquired 630,000 · Balance 630,000 F3: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof. F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-07-16 | Direct | 315,000 |
Reported balance
After 2025-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-16 · Grant · Acquired 315,000 · Balance 315,000 F4: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering"). F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2035-07-16 | Direct | 315,000 |
Reported balance
After 2025-07-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-16 · Grant · Acquired 315,000 · Balance 315,000 F5: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering. F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.
F2: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.
F3: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.
F4: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").
F5: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 19, 2017 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001562180-17-002292 · primarydocument.xml · derivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.expiration_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document |
| June 10, 2017 Filed Jun 14, 2017 00:12 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000067 · wf-form4_149739911768796.xml · derivative · entry 1 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-06-09 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares of common stock subject to the option shall vest monthly beginning on July 10, 2017, such that all of the shares of common stock subject to the option are vested by June 10, 2021, subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan (the "Plan")) through each vesting date; provided, that, 100% of the unvested portion of the option, if any, shall vest in the event of a termination without cause following a Change in Control (as defined in the Plan). Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:06 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 3,900 | $3.12 | $12,182.04 |
DisclosureSEC source: 0001280776-17-000059 · wf-form4_149703879137117.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.15. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 991 | $9.20 | $9,119.28 |
DisclosureSEC source: 0001562180-17-001430 · primarydocument.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,677 F1 · shares: Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. F2 · price: The price reported is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.19 to $9.21, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| January 03, 2017 Filed Jan 3, 2017 21:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,980 | $10.46 | $20,711.00 |
DisclosureSEC source: 0001562180-17-000081 · primarydocument.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,668 F1 · security: 47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date. F2 · shares: Shares sold by reporting person pursuant to a 10b5-1 plan in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1. F3 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.42 to $10.58, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 23, 2016 Filed Jan 17, 2017 21:01 UTC | IMMUNIC, INC. VTL · Entity 6306 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001280776-17-000003 · wf-form5_148468690602702.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,324 F1 · kind: Shares gifted by reporting person for no consideration. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,981 | $8.96 | $17,746.00 |
DisclosureSEC source: 0001562180-16-003208 · primarydocument.xml · nonDerivative · entry 1 Nash Duane · CIK 0001591098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,648 F1 · security: 47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date. F2 · shares: Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1. F3 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.88 to $9.00, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.